Literature DB >> 2242060

The post-occlusive hyperemic response in patients with systemic sclerosis.

F M Wigley1, R A Wise, J Mikdashi, S Schaefer, R J Spence.   

Abstract

We investigated post-ischemic hyperreactive cutaneous blood flow in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis (SSc). Reactive hyperemia was measured over a locally warmed area of skin, using a laser Doppler flowmeter, following 5 minutes of suprasystolic occlusion of blood flow. We found that patients with primary Raynaud's phenomenon had normal post-ischemic blood flow compared with normal controls. In contrast, patients with SSc had reduced levels of baseline and peak blood flow compared with either the primary Raynaud's phenomenon patients or the normal subjects. Infusion of carbaprostacyclin, a potent prostacyclin analog vasodilator, did not increase blood flow in the SSc patients, nor did it restore the reactive hyperemic response. These findings are consistent with the hypothesis that patients with the nonvasoconstricted condition of SSc have fixed structural defects that limit cutaneous microvascular blood flow.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2242060     DOI: 10.1002/art.1780331103

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  10 in total

Review 1.  Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis.

Authors:  A L Herrick; S Clark
Journal:  Ann Rheum Dis       Date:  1998-02       Impact factor: 19.103

Review 2.  A vascular mechanistic approach to understanding Raynaud phenomenon.

Authors:  Nicholas A Flavahan
Journal:  Nat Rev Rheumatol       Date:  2014-12-23       Impact factor: 20.543

3.  Exercise-induced brachial artery blood flow and vascular function is impaired in systemic sclerosis.

Authors:  Daniel R Machin; Heather L Clifton; Ryan S Garten; Jayson R Gifford; Russell S Richardson; D Walter Wray; Tracy M Frech; Anthony J Donato
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-09-30       Impact factor: 4.733

4.  Discrepancy between simultaneous digital skin microvascular and brachial artery macrovascular post-occlusive hyperemia in systemic sclerosis.

Authors:  Matthieu Roustit; Grant H Simmons; Jean-Philippe Baguet; Patrick Carpentier; Jean-Luc Cracowski
Journal:  J Rheumatol       Date:  2008-06-15       Impact factor: 4.666

5.  Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management.

Authors:  Zsuzsanna H McMahan; Fredrick M Wigley
Journal:  Int J Clin Rheumtol       Date:  2010

6.  Capillaroscopy as an Outcome Measure for Clinical Trials on the Peripheral Vasculopathy in SSc-Is It Useful?

Authors:  Maurizio Cutolo; Alberto Sulli; Carmen Pizzorni; Vanessa Smith
Journal:  Int J Rheumatol       Date:  2010-08-16

7.  Local hyperemia to heating is impaired in secondary Raynaud's phenomenon.

Authors:  Aude Boignard; Muriel Salvat-Melis; Patrick H Carpentier; Christopher T Minson; Laurent Grange; Catherine Duc; Françoise Sarrot-Reynauld; Jean-Luc Cracowski
Journal:  Arthritis Res Ther       Date:  2005-07-19       Impact factor: 5.156

Review 8.  Methods for the morphological and functional evaluation of microvascular damage in systemic sclerosis.

Authors:  Barbara Ruaro; Vanessa Smith; Alberto Sulli; Saskia Decuman; Carmen Pizzorni; Maurizio Cutolo
Journal:  Korean J Intern Med       Date:  2014-12-30       Impact factor: 2.884

9.  Impairment of microcirculation and vascular responsiveness in adolescents with primary Raynaud phenomenon.

Authors:  Bernadett Mosdósi; Kata Bölcskei; Zsuzsanna Helyes
Journal:  Pediatr Rheumatol Online J       Date:  2018-03-23       Impact factor: 3.054

10.  Innovations in the Assessment of Primary and Secondary Raynaud's Phenomenon.

Authors:  Barbara Ruaro; Vanessa Smith; Alberto Sulli; Carmen Pizzorni; Samuele Tardito; Massimo Patané; Sabrina Paolino; Maurizio Cutolo
Journal:  Front Pharmacol       Date:  2019-04-16       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.